Samarth Kulkarni Sells 9,973 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 9,973 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the sale, the chief executive officer now directly owns 180,890 shares in the company, valued at $7,673,353.80. This trade represents a 5.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Wednesday, February 19th, Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $41.99 on Friday. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $75.91. The company has a 50-day simple moving average of $43.03 and a 200-day simple moving average of $45.63. The firm has a market capitalization of $3.60 billion, a PE ratio of -9.61 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC boosted its stake in CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the period. Capital International Investors raised its position in shares of CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after buying an additional 816,789 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after buying an additional 1,074,238 shares in the last quarter. State Street Corp raised its position in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares in the last quarter. Finally, FMR LLC raised its position in shares of CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after buying an additional 23,075 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CRSP. Barclays lifted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Truist Financial lifted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Stifel Nicolaus decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Bank of America decreased their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, The Goldman Sachs Group decreased their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.